Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 2/2017

Open Access 01-12-2017 | Original Research

Deaths from Opioid Overdosing: Implications of Coroners’ Inquest Reports 2008–2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study

Authors: Elspeth E. Shipton, Ashleigh J. Shipton, Jonathan A. Williman, Edward A. Shipton

Published in: Pain and Therapy | Issue 2/2017

Login to get access

Abstract

Introduction

In the late 1990s multiple physicians and advocacy organizations promoted increased use of opioids for the treatment of acute, chronic and cancer pain. There has been an exponential growth in opioid prescribing in the last 20 years in the United States of America, in Australia, and in other developed Western countries. There are negative consequences associated with the liberal use of opioids. The primary aim of this population-based cohort study is to investigate the opioid-related death rate in New Zealand between 1 January 2008 and 31 December 2012. The secondary aims of this cohort study are: (1) to compare the opioid-related death rate per population in New Zealand in 2001/2002 with that between 2011/2012; (2) to investigate the number of opioid prescriptions in New Zealand between 2001 and 2012; (3) to compare the opioid-related death rate per population in New Zealand between 2001 and 2012 with the number of opioid prescriptions in New Zealand between 2001 and 2012.

Methods

Permission to access records from the Coronial Services Office in Wellington for 2008–2012 was acquired. Permission to access records for prescriptions containing opioids (dose and formulation) was obtained from the Pharmaceutical Collection.

Results

The rate of opioid-related deaths in New Zealand has increased by 33% from 2001 to 2012. More than half of the opioid-related deaths between 2008 and 2012 were unintentional opioid overdoses. Opioid analgesic deaths were most likely due to methadone, morphine and codeine prescribed by healthcare professionals. That 179 of these opioid-related deaths between 2008 and 2012 were unintentional opioid overdoses, and thus could have been avoided, is tragic. This study shows that there was a steady annual increases in opioid prescriptions in New Zealand from 2001 to 2012. This rise in opioid analgesic deaths was associated with the increases in the numbers of opioid prescriptions.

Conclusion

A multifaceted national public health approach is needed to bring together the various stakeholders involved with pain management, opioid dependence, opioid availability and opioid diversion. There needs to be a targeted approach to educate current and future medical practitioners regarding the appropriate use of opioid prescriptions for the management of pain, as well as a strengthening of primary, secondary and tertiary resources to support medical practitioners managing their patients who suffer with pain.
Literature
1.
Cheatle MD. Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015;16[Suppl 1]:S3–8.CrossRefPubMed
2.
Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171–86.CrossRefPubMed
3.
Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.PubMed
4.
Kanouse AB, Compton P. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother. 2015;29(2):102–14.CrossRefPubMed
5.
Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I—evidence assessment. Pain Phys. 2012;15[3 Suppl]:S1–65.
6.
Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78(5):1159–66.CrossRefPubMedPubMedCentral
7.
Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:Cd006605.
8.
9.
Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother. 2011;25(1):6–18.CrossRefPubMed
10.
Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(16):1573–4.PubMed
11.
12.
Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. MMWR Morb Mortal Wkly Rep. 2013;62(26):537–42.
13.
Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.CrossRefPubMed
14.
Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980–2008. NCHS Data Brief. 2011;81:1–8.
15.
Reith D, Fountain J, Tilyard M. Opioid poisoning deaths in New Zealand (2001–2002). N Z Med J. 2005;118(1209):U1293.PubMed
16.
National Coronial Information System (NCIS). CR15-19. 2007–2015. Southbank, Australia: NCIS
17.
18.
19.
Monheit B, Pietrzak D, Hocking S. Prescription drug abuse—a timely update. Aust Fam Physician. 2016;45(12):862–6.PubMed
20.
Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82.CrossRefPubMed
21.
Berecki-Gisolf J, Hassani-Mahmooei B, Clapperton A, McClure R. Prescription opioid dispensing and prescription opioid poisoning: population data from Victoria, Australia 2006 to 2013. Aust N Z J Public Health. 2017;41(1):85–91.CrossRefPubMed
22.
McMinn J. Opioid dependence, a life-threatening condition, is preventable. N Z Med J. 2014;127(1397):5.PubMed
23.
Robinson G, Judson G, Loan R, Bevin T, O’Connor P. Patterns of prescription drug misuse presenting to provincial drug clinics. N Z Med J (Online). 2011;124(1336):62–7.
24.
25.
Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644–56.CrossRefPubMed
26.
27.
Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy. 2014;25(6):1124–30.CrossRefPubMed
28.
29.
30.
Davis A, Davis K, Gerard C, Goyal S, Jackson G, James C, et al. Opioid rain: opioid prescribing is growing and practice is diverging. N Z Med J. 2016;129(1440):11–7.PubMed
31.
Deering D, Sellman JD, Adamson S. Opioid substitution treatment in New Zealand: a 40 year perspective. N Z Med J. 2014;127(1397):57–66.PubMed
32.
Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99(8):978–88.CrossRefPubMed
33.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:Cd002207.
34.
Roxburgh A, Hall WD, Burns L, Pilgrim J, Saar E, Nielsen S, et al. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Med J Aust. 2015;203(7):299.CrossRefPubMed
35.
Nielsen S, Bruno R, Murnion B, Dunlop A, Degenhardt L, Demirkol A, et al. Treating codeine dependence with buprenorphine: dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug Alcohol Rev. 2015;35:70–75.
36.
Chidambaran V, Sadhasivam S, Mahmoud M. Codeine and opioid metabolism: implications and alternatives for pediatric pain management. Curr Opin Anaesthesiol. 2017;30(3):349–56.
37.
Tverdohleb T, Dinc B, Knezevic I, Candido KD, Knezevic NN. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opin Drug Metab Toxicol. 2016;12(11)1303–11.
38.
Nielsen S, Murnion B, Dunlop A, Degenhardt L, Demirkol A, Muhleisen P, et al. Comparing treatment-seeking codeine users and strong opioid users: findings from a novel case series. Drug Alcohol Rev. 2015;34(3):304–11.CrossRefPubMed
39.
40.
Dyer O. Kentucky seeks $1bn from Purdue Pharma for misrepresenting addictive potential of oxycodone. BMJ. 2014;349:g6605.CrossRefPubMed
41.
42.
Radbruch L, Glaeske G, Grond S, Münchberg F, Scherbaum N, Storz E, et al. Topical review on the abuse and misuse potential of tramadol and tilidine in Germany. Subst Abuse. 2013;34(3):313–20.CrossRef
43.
Bush DM. Emergency department visits for drug misuse or abuse involving the pain medication tramadol. The CBHSQ report. Rockville: Substance Abuse and Mental Health Services Administration (US); 2013.
44.
45.
Taghogho Agarin M, Andrea Trescot M, Aniefiok Agarin M. Reducing opioid analgesic deaths in America: what health providers can do. Pain Phys. 2015;18:E307–22.
46.
Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57(11):1269–76, e419–28.
47.
Al-Adhami N, Whitfield K, North A. Changing prescribing culture—a focus on codeine postpartum. Arch Dis Child. 2016;101(9):e2.CrossRefPubMed
48.
49.
Faculty of Pain Medicine Australian and New Zealand College of Anaesthetists. Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain—position statement. http://​www.​fpm.​anzca.​edu.​au/​. 2015.
50.
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63–75.CrossRef
51.
52.
Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265–9.CrossRefPubMed
53.
Frenk SM, Porter KS, Paulozzi LJ. Prescription opioid analgesic use among adults: united States, 1999-2012. NCHS Data Brief. 2015;189:1–8.
54.
Metadata
Title
Deaths from Opioid Overdosing: Implications of Coroners’ Inquest Reports 2008–2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study
Authors
Elspeth E. Shipton
Ashleigh J. Shipton
Jonathan A. Williman
Edward A. Shipton
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 2/2017
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-017-0080-7

Other articles of this Issue 2/2017

Pain and Therapy 2/2017 Go to the issue

Erratum

Erratum to: Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set

Review

Hopes for the Future of Pain Control

Review

Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set

Review

Consensus Statement for Clinical Pathway Development for Perioperative Pain Management and Care Transitions

Review

Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review

Review

A Review of Current and Emerging Approaches to Pain Management in the Emergency Department

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits